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ofBACKGROUND Current guidelines generally recommend watchful waiting until symptoms emerge for aortic valve
replacement (AVR) in asymptomatic patients with severe aortic stenosis (AS).
OBJECTIVES The study sought to compare the long-term outcomes of initial AVR versus conservative strategies
following the diagnosis of asymptomatic severe AS.
METHODS We used data from a large multicenter registry enrolling 3,815 consecutive patients with severe AS (peak
aortic jet velocity >4.0 m/s, or mean aortic pressure gradient >40 mm Hg, or aortic valve area <1.0 cm2) between
January 2003 and December 2011. Among 1,808 asymptomatic patients, the initial AVR and conservative strategies were
chosen in 291 patients, and 1,517 patients, respectively. Median follow-up was 1,361 days with 90% follow-up rate at
2 years. The propensity score–matched cohort of 582 patients (n ¼ 291 in each group) was developed as the main analysis
set for the current report.
RESULTS Baseline characteristics of the propensity score–matched cohort were largely comparable, except for the
slightly younger age and the greater AS severity in the initial AVR group. In the conservative group, AVR was performed in
41% of patients during follow-up. The cumulative 5-year incidences of all-cause death and heart failure hospitalization
were signiﬁcantly lower in the initial AVR group than in the conservative group (15.4% vs. 26.4%, p ¼ 0.009; 3.8% vs.
19.9%, p < 0.001, respectively).
CONCLUSIONS The long-term outcome of asymptomatic patients with severe AS was dismal when managed conser-
vatively in this real-world analysis and might be substantially improved by an initial AVR strategy. (Contemporary Outcomes
After Surgery and Medical Treatment in Patients With Severe Aortic Stenosis Registry; UMIN000012140)
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AS = aortic stenosis
AVA = aortic valve area
AVR = aortic valve
replacement
HF = heart failure
IQR = interquartile range
LVEF = left ventricular ejection
fraction
PG = pressure gradient
STS = Society of Thoracic
Surgeons
Vmax = peak aortic jet velocity
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2828A ortic stenosis (AS) is a slowly pro-gressive disease and survival duringthe asymptomatic phase of AS is
similar to that of age-matched controls with
a low risk of sudden death when patients
are followed prospectively and promptly
report symptom onset (1–3). The potential
beneﬁts of aortic valve replacement (AVR)
in asymptomatic patients with severe AS
have not been thought to outweigh the oper-
ative mortality of AVR (4,5). Thus, current
guidelines generally recommend a strategy
of watchful waiting until symptoms emerge
for AVR in asymptomatic patients with se-
vere AS (6).SEE PAGES 2839 AND 2842However, the recommendation is based on previ-
ous small single-center studies that sought to eval-
uate symptoms and/or AVR, rather than mortality as a
primary outcome measure (1–3,7). A multicenter
study design seemed to be crucial for extrapolating
results into real clinical practice, because the quality
of echocardiographic examination, the manner of
patient follow-up, and the operative mortality of AVR
might vary between centers. Furthermore, there is no
large-scale study comparing an initial AVR strategy
with the conservative strategy in asymptomatic pa-
tients with severe AS except for 1 small single-center
observational study in patients with very severe AS
(8). Also, patient demographics, age, and operative
mortality of AVR in contemporary clinical practice
may be different from those reported in previous
studies (1–3,9–13). There is an obvious clinical need to
evaluate the balance between risks and beneﬁts of
AVR in asymptomatic patients with severe AS in
contemporary clinical practice.
Therefore, we sought to compare an initial AVR
strategy with the conservative strategy to assess long-, Japan; zzzDepartment of Cardiology, National Hospital Or
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large Japanese multicenter registry of consecutive
patients with severe AS.
METHODS
STUDY POPULATION. The CURRENT AS (Contempo-
rary outcomes after sURgery and medical tREatmeNT
in patients with severe Aortic Stenosis) registry is a
retrospective, multicenter registry enrolling consec-
utive patients with severe AS among 27 centers
(of which 20 had an on-site surgical facility) in Japan
between January 2003 and December 2011. We
searched the hospital database of transthoracic
echocardiography, and enrolled consecutive patients
who met the deﬁnition of severe AS (peak aortic jet
velocity [Vmax] >4.0 m/s, mean aortic pressure
gradient [PG] >40 mm Hg, or aortic valve area
[AVA] <1.0 cm2) for the ﬁrst time during the study
period (6). We excluded patients with a history of
aortic valve repair/replacement/plasty or percuta-
neous aortic balloon valvuloplasty. The institutional
review boards in all 27 participating centers (Online
Appendix) approved the protocol. Written informed
consent from each patient was waived in this retro-
spective study, because we used clinical information
obtained in routine clinical practice, and no patients
refused to participate in the study when contacted for
follow-up.
Among 3,815 patients enrolled in the registry, there
were 2,005 patients with and 1,808 patients without
AS-related symptoms at the time of index echocar-
diography, excluding 2 patients whose symptomatic
status was not available. In this primary report from
the CURRENT AS registry, 1,808 asymptomatic pa-
tients were subdivided into the initial AVR group
(n ¼ 291) and the conservative group (n ¼ 1,517) ac-
cording to treatment strategy selected after the index
echocardiography (Figure 1). Baseline characteristicsganization Kyoto Medical Center, Kyoto, Japan;
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FIGURE 1 Study Flow
Study Population
3815 patients with severe AS
(Jan 2003–Dec 2011, 27 centers in Japan) Unknown symptomatic status:
2 patients
Symptomatic
2005 patients
Asymptomatic
1808 patients
Initial AVR group
905 patients
Initial conservative group
1100 patients
Initial AVR group
291 patients
Initial conservative group
1517 patients
Propensity–score matched
cohort
Initial AVR group
291 patients
Initial conservative group
291 patients
From a study population of 3,815 with severe aortic stenosis (AS), 291 of those patients who were asymptomatic underwent aortic valve
replacement (AVR) and were compared to 291 managed with a conservative strategy in a propensity score-matched cohort study.
J A C C V O L . 6 6 , N O . 2 5 , 2 0 1 5 Taniguchi et al.
D E C E M B E R 2 9 , 2 0 1 5 : 2 8 2 7 – 3 8 Initial AVR Versus Conservative Strategy
2829and 5-year clinical outcomes were compared between
the initial AVR and conservative groups. Because the
selection of initial AVR was determined by physi-
cians, and the characteristics were highly different
between groups, we developed a propensity score–
matched cohort of 582 patients (evenly divided be-
tween initial AVR and the conservative strategy) as
the main analysis set for the current report (Figure 1,
Online Figure 1). We also analyzed the entire cohort
of asymptomatic AS patients to explore the robust-
ness of our analyses. Initial AVR and initial conser-
vative strategies were compared by intention-to-treat
analysis regardless of the actual performance of AVR.
Follow-up commenced on the day of index
echocardiography.
All patients underwent a comprehensive 2-
dimensional and Doppler echocardiographic evalua-
tion in each participating center. Maximal velocity
(Vmax) and mean aortic PG were obtained with the use
of the simpliﬁed Bernoulli equation. AVA was calcu-
lated using the standard continuity equation, and
indexed to body surface area (14).
DATA COLLECTIONS AND DEFINITIONS. Collection
of baseline clinical information was conducted
through hospital chart or database review. Angina,
syncope, or heart failure (HF) including dyspnea were
regarded as AS-related symptoms. Follow-up data
were mainly collected through review of hospital
charts or collected through contact with patients,
relatives, and/or referring physicians using mail withquestions regarding survival, symptoms, and subse-
quent hospitalizations.
For the current analysis, primary outcome mea-
sures were all-cause death and HF hospitalization.
Cause of death was classiﬁed according to VARC
(Valve Academic Research Consortium) deﬁnitions,
and adjudicated by a clinical event committee (Online
Appendix) (15,16). Sudden death was deﬁned as un-
explained death in previously stable patients. Aortic
valve–related death included aortic procedure–related
death, sudden death, and death due to HF possibly
related to aortic valve. HF hospitalization was deﬁned
as hospitalization due to worsening HF requiring
intravenous drug therapy. Other clinical event deﬁ-
nitions are described in the Online Appendix.
STATISTICAL ANALYSIS. Categorical variables are
presented as numbers and percentages, and
compared using the chi-square test or the Fisher
exact test. Continuous variables were expressed as
the mean  SD or median (interquartile range ([IQR]).
Based on their distributions, continuous variables
were compared using the Student t test or Wilcoxon
rank sum test. We used the Kaplan-Meier method to
estimate cumulative incidence and assessed the dif-
ferences with the log-rank test.
A logistic regression model was used to develop
propensity-score for the choice of initial AVR with 15
independent variables relevant to the choice of initial
AVR listed in Table 1. The C statistic was 0.783 and the
coefﬁcients of the independent variables are shown
TABLE 1 Baseline Characteristics
Entire Cohort Propensity Score–Matched Cohort
Initial AVR
Group
(n ¼ 291)
Conservative
Group
(n ¼ 1,517) p Value
Initial AVR
Group
(n ¼ 291)
Conservative
Group
(n ¼ 291) p Value
Clinical characteristics
Age,* yrs 71.6  8.7 77.8  9.4 <0.001 71.6  8.7 73.1  9.3 0.047
Age $80 yrs† 49 (17) 700 (46) <0.001 49 (17) 48 (16) 0.91
Male*† 126 (43) 604 (40) 0.27 126 (43) 124 (43) 0.87
BMI, kg/m2 22.1  3.3 21.9  3.9 0.53 22.1  3.3 22.9  3.7 0.01
BMI <22 kg/m2*† 146 (50) 911 (60) 0.002 146 (50) 142 (49) 0.74
BSA, m2 1.51  0.17 1.46  0.18 <0.001 1.51  0.17 1.51  0.17 0.76
Hypertension* 188 (65) 1060 (70) 0.07 188 (65) 187 (64) 0.93
Current smoking* 22 (8) 73 (5) 0.054 22 (8) 25 (9) 0.65
History of smoking 74 (25) 328 (22) 0.15 74 (25) 63 (22) 0.28
Dyslipidemia 116 (40) 532 (35) 0.12 116 (40) 83 (29) 0.004
On statin therapy 72 (25) 392 (26) 0.69 72 (25) 59 (20) 0.20
Diabetes mellitus 59 (20) 375 (25) 0.10 59 (20) 66 (23) 0.48
On insulin therapy* 11 (4) 80 (5) 0.29 11 (4) 14 (5) 0.54
Prior myocardial infarction* 5 (2) 146 (10) <0.001 5 (2) 13 (4) 0.06
Prior PCI 21 (7) 265 (17) <0.001 21 (7) 31 (11) 0.15
Prior CABG 7 (2) 91 (6) 0.01 7 (2) 7 (2) 1.0
Prior open heart surgery† 13 (4) 152 (10) 0.003 13 (4) 18 (6) 0.36
Prior symptomatic stroke*† 25 (9) 228 (15) 0.004 25 (9) 24 (8) 0.88
Atrial ﬁbrillation or ﬂutter* 39 (13) 299 (20) 0.01 39 (13) 40 (14) 0.90
Aortic/peripheral vascular disease* 23 (8) 148 (10) 0.32 23 (8) 31 (11) 0.25
Serum creatinine, mg/dl* 0.8 (0.6–1.0) 0.9 (0.7–1.2) 0.45 0.8 (0.6–1.0) 0.8 (0.7–1.1) 0.77
Creatinine level >2 mg/dl† 34 (12) 215 (14) 0.26 34 (12) 39 (13) 0.53
Hemodialysis* 32 (11) 175 (12) 0.79 32 (11) 37 (13) 0.52
Anemia*†‡ 130 (45) 732 (48) 0.26 130 (45) 125 (43) 0.68
Liver cirrhosis (Child-Pugh B or C)*† 1 (0.3) 10 (0.7) 1.0 1 (0.3) 0 (0) 1.0
Malignancy 34 (12) 242 (16) 0.06 34 (12) 36 (12) 0.80
Malignancy currently under treatment*† 7 (2) 87 (6) 0.02 7 (2) 0 (0) 0.02
Chest wall irradiation† 1 (0.3) 11 (0.7) 0.70 1 (0.3) 0 (0) 0.32
Immunosuppressive therapy† 4 (1) 56 (4) 0.04 4 (1) 2 (1) 0.69
Chronic lung disease 27 (9) 134 (9) 0.81 27 (9) 29 (10) 0.78
Chronic lung disease
(moderate or severe)*†
2 (1) 41 (3) 0.04 2 (1) 2 (1) 1.0
Coronary artery disease* 61 (21) 427 (28) 0.01 61 (21) 74 (25) 0.20
Logistic EuroSCORE, % 5.5 (3.7–8.3) 9.0 (5.5–15.2) <0.001 5.5 (3.7–8.3) 6.2 (4.0–9.7) 0.03
EuroSCORE II, % 1.5 (1.1–2.3) 2.6 (1.6–3.8) <0.001 1.5 (1.1–2.3) 1.9 (1.2–2.7) 0.001
STS score (PROM), % 2.0 (1.4–3.3) 3.5 (2.1–5.4) <0.001 2.0 (1.4–3.3) 2.4 (1.6–4.1) 0.007
Etiology of aortic stenosis
Degenerative 220 (76) 1367 (90) <0.001 220 (76) 246 (85) 0.02
Congenital (unicuspid, bicuspid,
or quadricuspid)
53 (18) 86 (6) 53 (18) 33 (11)
Rheumatic 9 (3) 57 (4) 9 (3) 10 (3)
Infective endocarditis 3 (1) 1 (0.07) 3 (1) 0 (0)
Other 6 (2) 6 (0.4) 6 (2) 2 (0.7)
Continued on the next page
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2830in Online Table 1. Propensity score was calculated by
summing up all coefﬁcients multiplies corresponding
variables. To create the propensity score–matched
cohort, patients in the conservative group were
matched to those in the initial AVR group using a 1:1
greedy matching technique (17). We then calculated
the cumulative incidence using the propensity score–matched cohort. Not all relevant variables were well
matched, probably due to the many patients in the
conservative group. Therefore, we conducted an
adjusted analysis using Cox proportional hazard
models with the risk-adjusting variables of age, dys-
lipidemia, malignancy currently under treatment,
EuroSCORE II, and Society of Thoracic Surgeons (STS)
TABLE 1 Continued
Entire Cohort Propensity Score–Matched Cohort
Initial AVR
Group
(n ¼ 291)
Conservative
Group
(n ¼ 1,517) p Value
Initial AVR
Group
(n ¼ 291)
Conservative
Group
(n ¼ 291) p Value
Echocardiographic variables
Vmax, m/s 4.8  0.8 3.8  0.7 <0.001 4.8  0.8 4.4  0.9 <0.001
Vmax $5 m/s† 114 (39) 93 (6) <0.001 114 (39) 111 (38) 0.80
Vmax $4 m/s* 245 (84) 619 (41) <0.001 245 (84) 182 (63) <0.001
Peak aortic PG, mm Hg 93  32 59  23 <0.001 93  32 79  32 <0.001
Mean aortic PG, mm Hg 54  20 33  14 <0.001 54  20 45  20 <0.001
AVA (equation of continuity), cm2 0.67  0.16 0.79  0.16 <0.001 0.67  0.16 0.75  0.18 <0.001
AVA index, cm2/m2 0.45  0.11 0.55  0.11 <0.001 0.45  0.11 0.50  0.12 <0.001
Eligibility for severe AS
Vmax >4 m/s 240 (82) 559 (37) <0.001 240 (82) 175 (60) <0.001
Mean aortic pressure gradient >40 mm Hg 174/220 (79) 347/1,272 (27) <0.001 174/220 (79) 130/239 (54) <0.001
Vmax >4 m/s or mean aortic PG >40 mm Hg 243 (84) 573 (38) <0.001 243 (84) 179 (62) <0.001
AVA <1.0 cm2 alone with LVEF <50% 5 (2) 106 (7) <0.001 5 (2) 1 (0.3) 0.22
AVA <1.0 cm2 alone with LVEF $50% 43 (15) 838 (55) <0.001 43 (15) 111 (38) <0.001
LV end-diastolic diameter, mm 45  6 45  6 0.36 45  6 45  6 0.83
LV end-systolic diameter, mm 28  6 29  6 0.27 28  6 28  5 0.53
LVEF, %* 66.8  9.9 65.7  11.1 0.11 66.8  9.9 68.2  7.9 0.06
<40%† 4 (1) 53 (3) 0.06 4 (1) 0 (0) 0.12
<50% 19 (7) 123 (8) 0.36 19 (7) 2 (0.7) <0.001
IVST in diastole, mm 12  2 11  2 <0.001 12  2 12  2 0.07
PWT in diastole, mm 12  2 11  2 <0.001 12  2 11  2 0.06
Any combined valvular disease
(Moderate or severe)*†
81 (28) 479 (32) 0.21 81 (28) 93 (32) 0.28
Moderate or severe AR 55 (19) 238 (16) 0.17 55 (19) 62 (21) 0.47
Moderate or severe MS 7 (2) 42 (3) 0.73 7 (2) 10 (3) 0.46
Moderate or severe MR 26 (9) 187 (12) 0.10 26 (9) 26 (9) 1.0
Moderate or severe TR 22 (8) 194 (13) 0.01 22 (8) 26 (9) 0.55
TR pressure gradient $40 mm Hg* 21 (7) 152 (10) 0.14 21 (7) 24 (8) 0.64
Values are mean  SD, n (%), median (interquartile range), or n/n (%). *Potential independent variables selected for Cox proportional hazards models in the unmatched cohort. †Potential
independent variables relevant to the choice of initial aortic valve replacement (AVR) selected for logistic regression model to develop propensity score for the choice of initial AVR. ‡Anemia
was deﬁned by the World Health Organization criteria (hemoglobin <12.0 g/dl in women and <13.0 g/dl in men).
AR¼ aortic regurgitation; AVA¼ aortic valve area; BMI¼ body mass index; BSA¼ body surface area; CABG¼ coronary artery bypass grafting; IVST¼ interventricular septum thickness; LV¼
left ventricular; LVEF ¼ left ventricular ejection fraction; MR ¼ mitral regurgitation; MS ¼ mitral stenosis; PCI ¼ percutaneous coronary intervention; PG ¼ pressure gradient; PROM ¼
predicted risk of mortality; PWT ¼ posterior wall thickness; STS ¼ Society of Thoracic Surgeons; TR ¼ tricuspid regurgitation; Vmax ¼ peak aortic jet velocity.
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2831Predicted Risk of Mortality (PROM), as a sensitivity
analysis in the propensity score–matched cohort.
For the secondary analysis among the entire cohort of
1,808 asymptomatic patients, the 21 clinically rele-
vant factors listed in Table 1 were included in the Cox
proportional hazards models as the risk adjusting
variables and the centers were incorporated as the
stratiﬁcation variable. With the exception of age,
continuous variables were dichotomized by median
values or clinically meaningful reference values.
Because the difference in age between the 2 groups
was too large to allow the dichotomous approach, we
treated age as a continuous variable in the Cox pro-
portional hazards models. Proportional hazards as-
sumptions for the risk-adjusting variables including
the categorized age in quartiles, were assessed on
the plots of log (time) versus log [-log (survival)]stratiﬁed by the variable, and veriﬁed to be accept-
able. The risks of an initial AVR strategy relative to
conservative strategy for the clinical endpoints were
expressed as hazard ratios (HRs) and their 95% con-
ﬁdence intervals (CIs).
All statistical analyses were conducted by a
physician (T.T.) and a statistician (T.M.) with the use
of JMP 10.0.2 or SAS 9.4 (both SAS Institute Inc., Cary,
North Carolina). All reported p values were 2-tailed,
and p values <0.05 were considered statistically
signiﬁcant.
RESULTS
Baseline characteristics were signiﬁcantly different
between the initial AVR and conservative groups
before matching (Table 1). Patients in the
CENTRAL ILLUSTRATION Cumulative Outcomes: Conservative Versus Initial AVR Strategies
Taniguchi, T. et al. J Am Coll Cardiol. 2015; 66(25):2827–38.
Continued on the next page
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TABLE 2 Clinical Outcomes: Propensity Score–Matched Cohort
Initial AVR
Group*
(n ¼ 291)
Conservative
Group*
(n ¼ 291) HR (95% CI) p Value
Adjusted HR
(95% CI) p Value
All-cause death 40 (15.4) 69 (26.4) 0.60 (0.40–0.88) 0.009 0.64 (0.42–0.94) 0.02
Cardiovascular death 25 (9.9) 46 (18.6) 0.55 (0.33–0.88) 0.01 0.59 (0.35–0.96) 0.03
Aortic valve–related death† 13 (5.3) 33 (13.5) 0.39 (0.20–0.73) 0.003 0.42 (0.21–0.79) 0.006
Aortic valve procedure death† 8 (2.9) 5 (4.5) 1.58 (0.53–5.24) 0.41 1.69 (0.55–5.69) 0.36
Sudden death 8 (3.6) 18 (5.8) 0.46 (0.19–1.03) 0.06 0.43 (0.17–0.99) 0.049
Noncardiovascular death 15 (6.1) 23 (9.6) 0.71 (0.36–1.35) 0.30 0.74 (0.37–1.45) 0.38
Emerging symptoms related to AS 9 (3.2) 116 (46.3) 0.06 (0.03–0.11) <0.001 0.06 (0.03–0.11) <0.001
Heart failure hospitalization 10 (3.8) 50 (19.9) 0.18 (0.09–0.35) <0.001 0.19 (0.09–0.36) <0.001
Composite of aortic valve–related death or
hospitalization due to heart failure†
23 (8.9) 70 (25.6) 0.30 (0.19–0.48) <0.001 0.33 (0.20–0.52) <0.001
Surgical AVR/TAVI 287 (99.7) 118 (52.6) N/A — N/A —
PTAV 0 (0) 3 (1.4) N/A — N/A —
Myocardial infarction 3 (0.7) 6 (3.2) 0.49 (0.10–1.85) 0.29 0.49 (0.10–1.90) 0.31
Stroke 23 (9.5) 18 (5.2) 1.39 (0.75–2.63) 0.30 1.47 (0.79–2.78) 0.23
Coronary revascularization (PCI/CABG) 47 (16.4) 38 (17.2) 1.28 (0.83–1.97) 0.26 1.36 (0.88–2.11) 0.16
Life-threatening/disabling or major bleeding 16 (7.7) 14 (5.0) 1.12 (0.54–2.32) 0.76 1.19 (0.57–2.53) 0.64
Infective endocarditis 8 (3.5) 2 (1.4) 3.91 (0.98–25.9) 0.054 4.10 (1.02–27.2) 0.047
Emerging atrial ﬁbrillation or ﬂutter 22 (8.6) 40 (18.0) 0.54 (0.32–0.90) 0.02 0.55 (0.31–0.92) 0.02
Noncardiac surgery under general or
spinal anesthesia
38 (13.9) 39 (20.6) 0.96 (0.61–1.50) 0.86 0.97 (0.61–1.53) 0.88
Values are n (%) unless otherwise indicated. *Number of patients with at least 1 event reported as cumulative 5-year incidence n (%). The number of patients with at least 1
event was counted through the entire follow-up period, while the cumulative incidence was truncated at 5 years. †Any death during the hospitalization for surgical or
transcatheter aortic valve implantation (TAVI) was regarded as aortic procedure–related death. Aortic valve–related death included aortic procedure–related death, sudden
death, and death due to heart failure. Heart failure hospitalization was deﬁned as hospitalization due to worsening heart failure requiring intravenous drug therapy.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; N/A ¼ not assessed; PTAV ¼ percutaneous transluminal aortic valvuloplasty; other abbreviations as in Table 1.
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2833conservative group were much older (77.8  9.4 years
vs. 71.6  8.7 years, p < 0.001) and more often had
prior symptomatic stroke, atrial ﬁbrillation or ﬂutter,
malignancy currently under treatment, chronic lung
disease, and coronary artery disease. Patients in the
initial AVR group, on the other hand, had greater AS
severity than those in the conservative group. There
were 247 patients who were regarded as ineligible for
AVR by the attending physicians, although the deci-
sion regarding the ineligibility for AVR was not uni-
form in this retrospective study. Physicians had 1 or
more reasons for ineligibility: extreme old age in
170 patients; reduced cognitive function in 53
patients; serious comorbid conditions that limit life
expectancy in 43 patients; renal failure in 26
patients; muscle weakness in 26 patients; anatomicFrom a large multicenter registry, patients with asymptomatic severe aor
(AVR) or a conservative strategy of watchful waiting; a propensity-match
the conservative group, AVR was performed in 118 patients (41%) durin
patients underwent AVR between 3 and 6 months after initial diagnosis
incidences of all-cause death and heart failure hospitalization were signi
TAVI ¼ transcatheter aortic valve implantation.
CENTRAL ILLUSTRATIONfactors that precluded or increased the risk of car-
diac surgery, such as a porcelain aorta, prior radia-
tion, or an arterial bypass graft in 22 patients;
reduced pulmonary function in 14 patients; malnu-
trition in 10 patients; and severe liver cirrhosis in
2 patients.
Among 291 patients referred for AVR despite
absence of symptoms related to AS, 184 (63%) pa-
tients had 1 or more formal indications for AVR;
very severe AS (Vmax $5.0 m/s or mean aortic
PG $60 mm Hg) in 118 patients (41%), left ventricular
dysfunction (deﬁned as left ventricular ejection
fraction [LVEF] <50%) in 19 patients (7%), candidates
for other cardiac surgery in 24 patients (8%), rapid
hemodynamic progression in 32 patients (11%), and
active infective endocarditis in 1 patient (0.3%).tic stenosis (AS) were initially managed with aortic valve replacement
ed cohort of 582 patients (n¼ 291 in each group) was studied here. In
g follow-up while in the initial AVR group, a large proportion of
due to scheduling and preoperative testing. The cumulative 5-year
ﬁcantly lower in the initial AVR group than in the conservative group.
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2834Baseline characteristics of the initial AVR and
conservative groups in the propensity score–matched
cohort were much more comparable than those in the
entire cohort except for the slightly younger age, a
slightly lower STS score, and the greater AS severity
in the initial AVR group (Table 1). Patients in the
matched cohort had a mean age in the early 70s, and
relatively low STS PROM score. Regarding classiﬁca-
tion of severe AS, 43 patients (15%) in the initial AVR
group and 111 patients (38%) in the conservative
group were included on the basis of AVA <1.0 cm2
alone (LVEF $50%) with less severe Vmax and mean
aortic PG (Table 1).
CLINICAL OUTCOMES IN THE PROPENSITY SCORE–
MATCHED COHORT. In the initial AVR group, sur-
gical AVR was actually performed in 286 (98%) pa-
tients. One patient underwent transcatheter AVR
with a median interval of 44 days from the index
echocardiography (Table 2, Central Illustration). In
the remaining 4 patients, 2 patients died suddenly,
another died of respiratory failure while awaiting
AVR, and the fourth was lost to follow-up on day 15.
The 30-day mortality rate after AVR was 1.4% in the
initial AVR group.
Among 291 patients in the conservative group, AVR
was performed in 118 patients (41%) during follow-up
with a median interval of 780 days from index echo-
cardiography (Central Illustration). Among 116 pa-
tients (40%) with emerging symptoms related to AS
during follow-up in the conservative group, AVR was
performed in 80 patients (69%) with median interval
of 72 (IQR: 42 to 121) days after symptom onset. AVR
was performed in 30 patients (67%) of 45 who pre-
sented with New York Heart Association functional
class III or IV HF (Online Table 2).
The cumulative 5-year incidence of all-cause death
was signiﬁcantly lower in the initial AVR group
than in the conservative group (15.4% vs. 26.4%,
p ¼ 0.009) (Table 2, Central Illustration). The cumu-
lative 5-year incidences of cardiovascular death and
aortic valve–related death were also signiﬁcantly
lower in the initial AVR group than in the conserva-
tive group (9.9% vs. 18.6%, p ¼ 0.01; and 5.3% vs.
13.5%, p ¼ 0.003, respectively). The cumulative
5-year incidence of sudden death trended lower in
the initial AVR group than in the conservative group
(3.6% vs. 5.8%, p ¼ 0.06). Among 46 patients with
cardiovascular death in the conservative group,
HF (9 patients who did not undergo AVR despite
symptoms) and sudden death (8 patients who did not
undergo AVR despite symptoms, and 10 patients
without symptoms) were the dominant causes of
cardiovascular death (Online Table 3). The initial AVR
strategy as compared with the conservative strategywas also associated with markedly lower cumulative
5-year incidences of emerging symptoms related to
AS and HF hospitalization (3.2% vs. 46.3%, p < 0.001;
and 3.8% vs. 19.9%, p < 0.001, respectively) (Table 2,
Central Illustration, Figure 2). The results from the
adjusted analysis conducted as a sensitivity analysis
were fully consistent with those from the unadjusted
analysis (Table 2).
CRUDE CLINICAL OUTCOMES IN THE ENTIRE COHORT.
Among 1,808 asymptomatic patients with severe AS,
median follow-up interval after the index echocar-
diography was 1,361 (IQR: 1,055 to 1,697) days with
90% follow-up rate at 2-year. Among 1,517 patients in
the conservative group, follow-up information was
collected from the hospital charts of the participating
centers in 1,311 patients (86.4%). AVR was performed
in 392 patients (26%) during follow-up with a median
interval of 788 days (Table 3, Online Figure 2). The
30-day mortality rate after AVR was 2.6% in the
conservative group, which tended to be higher than
that in the initial AVR group, but without signiﬁcant
difference (p ¼ 0.29). Among 492 patients with
emerging symptoms related to AS during follow-up
in the conservative group, AVR was performed in
239 patients (49%) with median interval of 70
(IQR: 41 to 131) days after onset of symptoms. AVR
was performed in only 74 of 201 (37%) patients pre-
senting with New York Heart Association functional
class III or IV HF. Among 127 patients who presented
with New York Heart Association functional class III
or IV HF, but who did not undergo AVR, 96 (76%)
patients died with a median interval of 95 (IQR: 11
to 467) days after symptom onset (Online Table 2).
Among 679 patients who underwent AVR in the
present study, AVR after symptom development
during follow-up (n ¼ 247, including 8 patients
who became symptomatic at time of AVR) was
associated with higher 30-day operative mortality
than AVR while asymptomatic (n ¼ 432; 3.7% vs.
1.2%, p ¼ 0.03).
Cumulative 5-year incidence of all-cause death was
signiﬁcantly lower in the initial AVR group than in the
conservative group (Table 3, Online Figure 2). Among
582 (32%) patients who died during follow-up, HF and
sudden death were the predominant causes of death
in the conservative group (101 and 82 patients,
respectively), while those were uncommon causes of
death in the initial AVR group (1 and 8 patients,
respectively) (Online Table 4). The cumulative 5-year
incidence of HF hospitalization was also signiﬁcantly
lower in the initial AVR group (Table 3, Online
Figure 2). The cumulative 5-year incidence of sud-
den death was 7.6% (1.5%/year) in the conservative
group versus 3.6% (0.7%/year) in the initial AVR
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Cumulative incidences of aortic valve-related death (A) and particularly emerging symp-
toms related to AS (B) were signiﬁcantly lower with the initial AVR strategy in the
propensity-score matched cohort. Abbreviations as in Figure 1.
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2835group. Among 82 patients experiencing sudden death
in the conservative group, 57 patients (70%) died
abruptly without preceding symptoms and 32 (56%)
of these sudden deaths occurred within 3 months of
the last clinical follow-up visit.
The lower cumulative incidences of all-cause death
and HF hospitalization in the initial AVR group
compared to the conservative group were consis-
tently seen in the 2 subgroups of patients with or
without current recommendations for AVR such as
very severe AS at low surgical risk or severe AS with
left ventricular dysfunction (Online Figure 3).
ADJUSTED CLINICAL OUTCOMES IN THE ENTIRE
COHORT. The favorable effect of an initial AVR
strategy for the clinical outcomes was similarly
seen in the adjusted analysis of the entire cohort as
well as in the propensity score–matched analysis,
although the effect size was smaller in the propensity
score–matched cohort than in the entire cohort
(Table 3). The lower risks of an initial AVR strategy
relative to the conservative strategy for all-cause
death and HF hospitalization were consistently seen
in the 2 subgroups of patients with or without current
recommendations for AVR (Online Figure 3).
DISCUSSION
The main ﬁnding of this study was that compared to a
conservative “watchful waiting” approach, an initial
AVR strategy was associated with lower risk for all-
cause death and HF hospitalization in asymptomatic
patients with severe AS in a propensity score–
matched analysis (Central Illustration).
Although AVR is strongly recommended in symp-
tomatic patients with severe AS who are candidates
for surgery, management of asymptomatic patients
with severe AS remains controversial. Current
guidelines recommend a strategy of watchful waiting
until symptoms emerge for AVR in asymptomatic
patients with severe AS except for patients with left
ventricular dysfunction, very severe AS, need for
other cardiac surgery, or an abnormal exercise test
(6,18). However, the current large-scale multicenter
propensity score–matched analysis clearly demon-
strated the beneﬁts of an initial AVR strategy in
reducing mortality and HF hospitalization as
compared with a conservative strategy. The extent of
beneﬁt appeared to be similar regardless of the cur-
rent indications for AVR such as left ventricular
dysfunction or very severe AS.
Several important issues should be considered
regarding the clinical relevance of the watchful
waiting strategy for AVR. First, and most importantly,
the current recommendations for AVR are mainlydependent on the patient symptoms. However, many
patients with severe AS who could potentially beneﬁt
from AVR may not complain any symptoms because
of their sedentary lifestyle. It is often difﬁcult to
distinguish the nonspeciﬁc symptoms such as fatigue
and dyspnea on exertion from the true symptoms
of AS. In the asymptomatic patients with severe AS,
an exercise stress test is recommended to conﬁrm
both their asymptomatic status and hemodynamic
response to exercise (6,19). However, exercise testing
TABLE 3 Clinical Outcomes: Entire Cohort
Initial AVR
Group*
(n ¼ 291)
Conservative
Group*
(n ¼ 1,517)
Unadjusted HR
(95% CI) p Value
Adjusted HR
(95% CI) p Value
All-cause death 40 (15.4) 542 (41.7) 0.33 (0.23–0.44) <0.001 0.51 (0.35–0.72) <0.001
Cardiovascular death 25 (9.9) 323 (28.2) 0.34 (0.22–0.50) <0.001 0.47 (0.30–0.74) 0.001
Aortic valve–related death† 13 (5.3) 197 (19.2) 0.29 (0.16–0.48) <0.001 0.40 (0.22–0.74) 0.004
Aortic valve-procedure death† 8 (2.9) 16 (1.8) 2.33 (0.94–5.30) 0.07 N/A —
Sudden death 8 (3.6) 82 (7.6) 0.43 (0.19–0.83) 0.01 0.67 (0.29–1.53) 0.34
Noncardiovascular death 15 (6.1) 219 (18.9) 0.30 (0.17–0.49) <0.001 0.58 (0.32–1.03) 0.06
Emerging symptoms related to AS 9 (3.2) 492 (45.0) 0.07 (0.03–0.12) <0.001 0.06 (0.03–0.12) <0.001
Heart failure hospitalization 10 (3.8) 284 (25.4) 0.14 (0.07–0.25) <0.001 0.21 (0.11–0.40) <0.001
A composite of aortic valve–related death or
hospitalization due to heart failure
23 (8.9) 368 (31.6) 0.26 (0.16–0.38) <0.001 0.34 (0.22–0.54) <0.001
Surgical AVR/TAVI‡ 287 (99.7) 392 (40.9) N/A — N/A —
PTAV 0 (0.0) 24 (2.5) N/A — N/A —
Myocardial infarction 3 (0.7) 34 (3.6) 0.39 (0.09–1.08) 0.07 1.10 (0.28–4.26) 0.89
Stroke 23 (9.5) 98 (8.1) 1.06 (0.66–1.64) 0.81 1.91 (1.12–3.26) 0.02
Coronary revascularization (PCI/CABG) 47 (16.4) 180 (16.6) 1.30 (0.93–1.78) 0.12 1.60 (1.08–2.38) 0.02
Life-threatening/disabling or major bleeding 16 (7.7) 84 (7.0) 0.85 (0.48–1.41) 0.54 1.56 (0.83–2.94) 0.16
Infective endocarditis 8 (3.5) 16 (1.7) 2.22 (0.90–5.06) 0.08 N/A —
Emerging atrial ﬁbrillation or ﬂutter 22 (8.6) 133 (13.4) 0.75 (0.46–1.15) 0.19 0.98 (0.59–1.61) 0.92
Noncardiac surgery under general or spinal anesthesia 38 (13.9) 186 (17.1) 0.95 (0.66–1.33) 0.76 1.26 (0.85–1.88) 0.25
Values are n (%) unless otherwise indicated. *Number of patients with at least 1 event reported as cumulative 5-year incidence n (%). The number of patients with at least 1
event was counted through the entire follow-up period, while the cumulative incidence was truncated at 5 years. †Any death during the hospitalization for surgical or TAVI was
regarded as aortic procedure–related death. Aortic valve–related death included aortic procedure–related death, sudden death, and death due to heart failure. Heart failure
hospitalization was deﬁned as hospitalization due to worsening heart failure requiring intravenous drug therapy. ‡TAVI was performed during follow-up in 1 patient in the initial
AVR group, and in 15 patients in the conservative group.
Abbreviations as in Tables 1 and 2.
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2836is not commonly performed in real clinical practice
due to safety concerns or cannot be performed in
many patients because of advanced age, limited ex-
ercise capacities, and comorbidities.
Additionally, prompt detection of symptoms dur-
ing follow-up is not always possible in clinical prac-
tice (6). Patients may not always be compliant to close
clinical follow-up (20). Indeed, in the current study,
severe HF was the initial symptom in a sizable pro-
portion of patients in the conservative group, for
whom AVR was less frequently performed than in
patients without severe HF, and mortality was
extremely high if AVR was not performed. It is
noteworthy that an initial AVR strategy was associ-
ated with markedly lower risk for HF hospitalization
than the conservative strategy; HF hospitalization
should be regarded as a very serious clinical event
in patients with severe AS. Also, the present study
and a prior large scale surgical report suggested
that AVR after symptom development carries higher
operative risk than AVR during the asymptom-
atic phase, although Brown et al. (21) reported
similar AVR operative mortality between symptom-
atic and asymptomatic patients from a single center
study (4).The annual rate of sudden death in the conserva-
tive group (1.5% in the current study) suggests that
the rate of sudden death during the asymptomatic
phase might be higher than previously reported
(<1.0%/year) (2,3,9). Finally, in the present study,
41% of patients managed conservatively required
AVR within a median follow up of 2 years, suggesting
little gain from waiting. Balancing the risks of
watchful waiting with the improvement in operative
mortality, AVR during the asymptomatic phase may
be a viable treatment option in severe AS patients at
low-risk for AVR.
STUDY LIMITATIONS. In that this was a retrospec-
tive study, we could not exclude the possibility of
ascertainment bias for symptoms related to AS at
baseline. However, we thoroughly reviewed all pa-
tient charts and referred to the hospital database
to evaluate symptomatic status. Also, we cannot
deny residual confounding and selection bias in
the comparison between initial AVR and conser-
vative strategies, although the characteristics of
the 2 groups were largely comparable after
propensity-score matching. Actually in the present
analysis, propensity-score matching did not com-
pletely eliminate the impact of differences in age
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: According to
propensity score-matched analysis of a registry database, a
strategy of earlier AVR in patients with asymptomatic severe AS
was associated with lower long-term risk of hospitalization for
HF or all-cause mortality compared with the strategy currently
recommended in clinical practice guidelines to await the onset of
symptoms before intervention.
TRANSLATIONAL OUTLOOK: Randomized trials are needed
to compare earlier AVR versus more conservative strategy of
delaying intervention until symptom onset in managing patients
with asymptomatic severe AS.
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2837as well as EuroSCORE and STS score in the 2
populations. However, results from the adjusted
analysis conducted as a sensitivity analysis were
fully consistent with those from the unadjusted
analysis.
Some patients also were included in this study on
the basis of AVA <1.0 cm2 alone (LVEF $50%) with
less severe Vmax and mean aortic PG. The imprecision
of assessing AVA by echocardiography with over-
estimation of AS severity in some patients is a
possible concern. However, the proportion of those
patients included on the basis of AVA <1.0 cm2 alone
was greater in the conservative group than in the
initial AVR group. Clinical outcomes were worse in
the conservative group than in the initial AVR group
despite more frequent inclusion of somewhat less
severe AS in the former group.
Finally, patient follow-up in this multicenter study
might have been less close than in the previous
single-center studies, therefore, emerging symptoms
related to AS might have been underestimated.
However, follow-up information in the conservative
group was collected from the hospital chart of
participating centers for 86.4% of patients, suggest-
ing that the majority of patients were followed by
cardiologists. It is important to note that even with
follow-up by cardiologists, presentation with severe
HF during follow-up was not uncommon in clinical
practice.CONCLUSIONS
The long-term outcome of asymptomatic patients
with severe AS was dismal when managed conserva-
tively in real-world clinical practice and might be
substantially improved by an initial AVR strategy.
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